Oncovision’s preclinical PET imaging business acquired in agreement with Bruker

PET and SPECT are key molecular imaging technologies for Bruker’s Preclinical Imaging division, allowing Bruker to offer the highest-performance SiPM-PET/SPECT/CT and integrated SiPM-PET/MR imaging systems.

Bruker today announced that it has signed an agreement to acquire the preclinical imaging business of Oncovision, a leading provider of innovative medical imaging devices used for the diagnosis of cancer. Financial terms of the agreement were not disclosed.

For the past five years, Bruker and Oncovision have partnered on an exclusive marketing agreement for Albira™ PET/SPECT/CT systems, and have developed the next-generation Albira Si with advanced Silicon photomultiplier (SiPM) technology for highest full field-of-view PET resolution and sensitivity.

Albira Si with advanced Silicone photomultiplier (SiPM) technology for highest full field-of-view PET resolution and sensitivity 

Oncovision and Bruker have also collaborated on a high-performance preclinical 3 Tesla SiPM-PET/MRI system, and are exhibiting a new, simultaneous SiPM-PET/MR insert for high-field magnets at WMIC 2016 in New York this week.

PET_Insert_pr07092016

Performance-leading Silicon photomultiplier (SiPM) PET insert for simultaneous PET/MRI (Positron Emission Tomography / Magnetic Resonance Imaging). 

With this planned acquisition, Bruker expects to strengthen its expertise and leadership in preclinical imaging. The unique, performance-leading SiPM PET technology and products developed by Oncovision in close collaboration with the molecular imaging institute I3M and the University of Valencia, offer outstanding spatial resolution across the full field of view (FOV), increasing the high-resolution FOV by an order of magnitude compared to traditional PET systems, thereby facilitating quantitative imaging investigations.”

Dr. Wulf I. Jung, President of Bruker’s Preclinical Imaging Division.

Dr. Jung continued: “This unique and proprietary PET technology is one of the most important imaging modalities for translational research imaging. Our successful collaboration with Oncovision has led to the recent introduction of the performance-leading Albira SiPET/SPECT/CT system, and it now has also resulted in the first PET insert for high-field MRI systems for simultaneous PET and MRI measurements.”

Ignasi Vivas, CEO of Oncovision, commented: “Bruker is the undisputed leader in preclinical imaging with a unique portfolio of imaging modalities. Our preclinical team is delighted to join a company so well known for their innovation and dedication to excellence. The combined resources will accelerate the development and integration of Bruker's molecular imaging technologies, and fulfill the growing demand from translational scientists.”

As part of the agreement, Oncovision will retain its clinical human imaging business, including the MAMMI PET, a breast cancer diagnostic device based on PET imaging. Closing of the acquisition is expected late in the fourth quarter of 2016, and is subject to closing conditions. A German-Spanish team of the law firm CMS acted as legal adviser to Bruker.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bruker BioSpin - NMR, EPR and Imaging. (2020, April 01). Oncovision’s preclinical PET imaging business acquired in agreement with Bruker. News-Medical. Retrieved on September 27, 2021 from https://www.news-medical.net/news/20160909/Oncovisions-preclinical-PET-imaging-business-acquired-in-agreement-with-Bruker.aspx.

  • MLA

    Bruker BioSpin - NMR, EPR and Imaging. "Oncovision’s preclinical PET imaging business acquired in agreement with Bruker". News-Medical. 27 September 2021. <https://www.news-medical.net/news/20160909/Oncovisions-preclinical-PET-imaging-business-acquired-in-agreement-with-Bruker.aspx>.

  • Chicago

    Bruker BioSpin - NMR, EPR and Imaging. "Oncovision’s preclinical PET imaging business acquired in agreement with Bruker". News-Medical. https://www.news-medical.net/news/20160909/Oncovisions-preclinical-PET-imaging-business-acquired-in-agreement-with-Bruker.aspx. (accessed September 27, 2021).

  • Harvard

    Bruker BioSpin - NMR, EPR and Imaging. 2020. Oncovision’s preclinical PET imaging business acquired in agreement with Bruker. News-Medical, viewed 27 September 2021, https://www.news-medical.net/news/20160909/Oncovisions-preclinical-PET-imaging-business-acquired-in-agreement-with-Bruker.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Bruker establishes new customer support center in the Middle East at King Abdullah University of Science and Technology Research Park